Navigation Links
Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America

FDA-Approved Study Aimed at Harnessing Immune System to Fight Tumors

CHICAGO, May 22 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA), a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, has begun accepting patients for an ovarian cancer vaccine clinical trial. The Phase I/II study, recently reviewed and cleared by the U.S. Food and Drug Administration (FDA), will evaluate the safety and efficacy of the unique ovarian cancer vaccine therapy for up to 42 patients with chemotherapy-resistant, advanced stage ovarian cancer.

The study will be conducted exclusively at CTCA at Midwestern Regional Medical Center in suburban Chicago. Eligible participants will be CTCA patients who have stage III or IV ovarian cancer and have tumor progression despite at least one, but no more than two, chemotherapy regimens. Participants in this clinical trial must first receive surgery at CTCA at Midwestern Regional Medical Center and localized chemotherapy infused directly into the abdomen (intraperitoneal chemotherapy), a standard of cancer care available to many CTCA patients. Patients become eligible for the ovarian cancer vaccine trial when it is determined that enough tumor cells can be harvested from the debulked tumor to create the ovarian cancer vaccine and the vaccine has passed rigid quality control testing.

CTCA will work with AVAX Technologies, Inc., to create a personalized ovarian cancer vaccine, using each patient's tumor cells that have been surgically removed at CTCA. These cells will be modified in the AVAX laboratories and will be designed to produce an immunologic response to treat the patient's ovarian cancer.

"The use of a systematic vaccine to sensitize the patient's immune system to fight their own tumors following localized, high-dose chemotherapy has not been attempted before," said Donald Braun, Ph.D., CTCA vice president for clinical research. Braun and Dr. Sybilann Williams, gynecologic oncologist and surgeon at CTCA along with Dr. David Berd, chief medical officer of AVAX, will serve as investigators.

"CTCA offers a powerful combination of traditional and innovative therapies provided by a team of cancer experts who work with each patient individually, to determine the appropriate combination of therapies to fight cancer," Dr. Williams said. "Ovarian cancer is a very complex disease that is often resistant to chemotherapy, radiation and surgery. CTCA will offer our patients the opportunity to be involved in another ground-breaking step in the fight against ovarian cancer."

The American Cancer Society ranks ovarian cancer as the eighth most common cancer among women, and it is the fifth leading cause of cancer-related deaths in women. It is estimated that there will be 21,650 new cases of ovarian cancer in the U.S. in 2008 and 15,520 cancer-related deaths. Ovarian cancer occurs in about one out of every 69 women, according to the Ovarian Cancer National Alliance.

"We are enthusiastic about receiving FDA clearance to start this important clinical trial and with the opportunity it affords us to collaborate with CTCA," stated AVAX's Dr. Berd. "Clearly, better treatments for ovarian cancer are needed and we hope the vaccine will eventually find its place as a relatively non-toxic therapeutic alternative for these patients.

More information about the vaccine trial, ovarian cancer, and ovarian cancer treatment can be found at Patients interested in the clinical trial may contact a CTCA Oncology Information Specialist at 877-98-TRIAL.

About Cancer Treatment Centers of America

Founded in 1988, Cancer Treatment Centers of America (CTCA) is a network of cancer treatment hospitals and community oncology programs in Illinois, Oklahoma, Pennsylvania and Washington - with a future location in Arizona scheduled to open in early 2009. CTCA provides a comprehensive, patient-centered treatment model that fully integrates conventional, state-of-the-art medical treatments with scientifically-supported complementary therapies such as nutrition, naturopathic medicine, psychological counseling, physical therapy and spiritual support to meet the special, whole-person needs of cancer patients with complex and advanced-stage disease. CTCA encourages patients and their families to participate in treatment decisions through its Patient Empowerment Medicine(SM) model. For more information about Cancer Treatment Centers of America, go to

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition, the company performs contract-manufacturing services for biological products for other pharmaceutical and biotechnology companies.

SOURCE Cancer Treatment Centers of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
2. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
3. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
4. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
5. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
10. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
11. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Post Your Comments:
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any ... opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with the ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):